Clinical Trial Update: A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib [Phase 3]

View source ↗

Summary

This update reports the results of a Phase 3 study comparing ripretinib to sunitinib in advanced gastrointestinal stromal tumors after imatinib treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• QINLOCK (ripretinib)
• Sutent (sunitinib)

Snippet

Sponsor: Deciphera Pharmaceuticals, LLC | Conditions: Gastrointestinal Stromal Tumors | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-01-02